Shots:

• Merck reports the launch of Ontruzant (trastuzumab-dttb)- a biosimilar referencing Herceptin and will be available in both 150mg single-dose vials at a WAC of ~$1-325 and 420mg multiple-dose vials at a WAC of ~ $3-709- representing a 15% discount to the current list price of Herceptin
• The biosimilar is being launched as a part of a development and commercialization agreement with Samsung Bioepis- under which Merck has right to commercialize the therapy in licensed territories- including the US while Samsung Bioepis is responsible for pre/clinical development- manufacturing- CTs and regulatory registration
• Ontruzant showed high bio-similarity to Herceptin in terms of safety- purity and potency of therapy and received the FDA’s approval in Jan’2019. Merck will support the commercialization of Ontruzant until the spinoff- which expected to take place in H1’21

Click here ­to­ read full press release/ article 

Ref: Merck | Image: Merck